Skip to main content

Oriahnn Side Effects

Generic name: elagolix / estradiol / norethindrone

Medically reviewed by Philip Thornton, DipPharm. Last updated on Jul 15, 2023.

Note: This document contains side effect information about elagolix / estradiol / norethindrone. Some dosage forms listed on this page may not apply to the brand name Oriahnn.

Applies to elagolix / estradiol / norethindrone: oral capsule.


Oral route (Capsule)

Thrombolic Disorders and Vascular EventsEstrogen and progestin combinations, including elagolix, estradiol, and norethindrone acetate plus elagolix, increase the risk of thrombotic or thromboembolic disorders, especially in women at increased risk for these events.Elagolix, estradiol, and norethindrone acetate plus elagolix is contraindicated in women with current or a history of thrombotic or thromboembolic disorders and in women at increased risk for these events including women over 35 years of age who smoke or women with uncontrolled hypertension.

Serious side effects of Oriahnn

Along with its needed effects, elagolix/estradiol/norethindrone may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking elagolix / estradiol / norethindrone:

Less common


Other side effects of Oriahnn

Some side effects of elagolix / estradiol / norethindrone may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

Less common

For Healthcare Professionals

Applies to elagolix / estradiol / norethindrone: oral capsule.


The more commonly reported adverse reactions have included hot flush, headache, fatigue, and metrorrhagia.[Ref]


Very common (10% or more): Hot flush (22%)

Common (1% to 10%): Hypertension

Uncommon (0.1% to 1%): Thrombotic events[Ref]

During clinical trials, 2 thrombotic events were reported (n=453). A woman with obesity developed thrombosis in her left calf after 30 days of treatment. A second woman developed a pulmonary embolism 8 months into treatment.

During clinical trials, maximum mean increases in systolic and diastolic blood pressure were 5.1 and 2.1 mmHg, respectively occurring at month 5 and month 4, respectively.[Ref]


During clinical trials, BMD was assessed by dual-energy X-ray absorptiometry (DXA). At 6 months, the percent change in lumbar spine BMD was -0.7% in women receiving this drug compared with -0.1% for placebo. For women treated with this drug for 12 months, 27% experienced a decline in lumbar spine BMD of greater than 3%; 1.7% experienced a decline of 8% or greater. Following cessation of therapy, continued bone loss was observed at the lumbar spine, total hip, and femoral neck in 24%, 32%, and 40% of women, respectively; partial recovery occurred in 46%, 33%, and 38% and full recovery was observed in 30%, 35%, and 22% at these same sites.[Ref]

Very common (10% or more): Loss of bone mineral density (BMD) in lumbar spine (27%)

Common (1% to 10%): Arthralgia[Ref]


Common (1% to 10%): Increased weight


During clinical trials, depression, depressed mood, and/or tearfulness were reported in 3% of women receiving this drug compared to 1% of placebo-treated women. In clinical trials for elagolix, a woman treated with lower dose elagolix alone completed suicide 2 days after elagolix discontinuation.[Ref]

Common (1% to 10%): Decreased libido; adverse mood changes including depression, depressed mood, tearfulness


Frequency not reported: Suicide[Ref]


Common (1% to 10%): Metrorrhagia[Ref]


Common (1% to 10%): Alopecia[Ref]


Common (1% to 10%): Transaminase elevations[Ref]

During clinical trials, ALT and AST elevations of up to 3 times the upper limit of normal (3 x ULN) occurred in 1.1% and 1.3% of women treated with this drug, respectively compared with 0% receiving placebo. Peak elevation in AST of almost 8 x ULN and ALT of 6 x ULN was reported.[Ref]


Uncommon (0.1% to 1%): Breast Cancer[Ref]

In phase 3 trials, 2 cases of breast cancer were reported among 453 women receiving this drug.[Ref]

Nervous system

Common (1% to 10%): Headache[Ref]


Common (1% to 10%): Fatigue[Ref]


Common (1% to 10%): Abdominal distension, vomiting[Ref]


Common (1% to 10%): Upper respiratory tract infection[Ref]


Common (1% to 10%): Influenza


1. Product Information. Oriahnn (elagolix / estradiol / norethindrone). AbbVie US LLC. 2020.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.